| Expression pattern: |
DN |
| Associated gene: |
PTEN, PI3K/AKT pathway, Ago2 |
| Associated microRNA: |
miR-21-5p |
| Biological function: |
Overexpression of circDDX17 enhanced sorafenib sensitivity, promoted apoptosis, inhibited EMT, reduced tumor growth, and suppressed HCC tumorigenesis. |
| Molecular mechanism: |
circDDX17 acts as a miR-21-5p sponge and regulates the miR-21-5p/PTEN/PI3K/AKT axis to suppress sorafenib resistance and HCC progression. |
| Biological pathway or process: |
PI3K/AKT (inhibits); apoptosis (promotes); EMT (inhibits); proliferation (inhibits); drug resistance (inhibits); chemoresistance (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model |
| Clinical significance: |
circDDX17 may provide novel biomarkers for the diagnosis, treatment and prognosis of HCC; circDDX17 expression was positively associated with HBV infection. |
| Description: |
circDDX17 is down-regulated in HCC tissues and cell lines. Its overexpression suppresses HCC tumorigenesis, reduces sorafenib resistance, promotes apoptosis, and inhibits EMT, partly through the miR-21-5p/PTEN/PI3K/AKT regulatory axis. |
| Confidence score: |
0.7581 |